Inspire Medical Systems, Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering

Download as PDF

MINNEAPOLIS (April 6, 2018) – Inspire Medical Systems, Inc. (“Inspire”), a medical technology
company focused on the development and commercialization of innovative and minimally invasive
solutions for patients with obstructive sleep apnea, announced today that it has filed a registration
statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial
public offering of its common stock. The number of shares to be offered and the price range for the
offering have not yet been determined. Inspire has applied to list its common stock on the New York
Stock Exchange under the ticker symbol “INSP.”

BofA Merrill Lynch and Goldman Sachs & Co. LLC are serving as joint lead book-running managers for
the proposed offering. Guggenheim Securities, Stifel, and Wells Fargo Securities are acting as co-
managers for the proposed offering.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating
to this offering, when available, may be obtained from any of the following sources:

  • BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-
    0001, Attention: Prospectus Department or via email: dg.prospectus_requests@baml.com; or
  • Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New
    York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com.

A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities
and Exchange Commission but has not yet become effective. These securities may not be sold nor may
offers to buy these securities be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there
be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical
Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that
provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
bob@lifesciadvisors.com
646-597-6989